Bloomberg View
Peak sales from drugs approved in 2014 will actually add up to less than those approved in 2013.
R&D Productivity 2014: A Breakthrough Year for Biopharma was referenced by Bloomberg View, in an article on the biotech bubble; specifically, the resurgence that took place in the biopharma industry in 2014 due to more drugs being aimed at smaller targets.